At least 15% of all known disease mutations can cause structural errors in the mRNA through a process called Alternative Splicing. Envisagenics is the first bioinformatics company developing a cloud-based software platform for the analysis of splicing, translating NextGen sequencing data into BioPharma R&D intelligence through a SaaS business model. Our team has developed novel software at Cold Spring Harbor Laboratory to reduce the time, cost and failure risk of preclinical therapeutic research. Envisagenics has a paying beta-customer in the field of RNA therapeutics and two examples of proof-of-concept validation in Breast Cancer and Spinal Muscular Atrophy.